Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 12:18:49-59.
doi: 10.2147/CIA.S361519. eCollection 2023.

Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults

Colin Tuft  1 , Elie Matar  2 , Zoe Menczel Schrire  2 , Ronald R Grunstein  2   3 , Brendon J Yee  1   2   3 , Camilla M Hoyos  2   4
Affiliations
Review

Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults

Colin Tuft et al. Clin Interv Aging. .

Abstract

Exogenous melatonin is commonly used for sleep disorders in older adults, and its use is increasing over time. It appears to have modest efficacy in treating insomnia and circadian rhythm sleep-wake disorders. Melatonin is commonly perceived to be a safe alternative to other hypnotics and is available without prescription in some jurisdictions. New evidence suggests that endogenous melatonin has pleomorphic effects on multiple organ systems, many of which are poorly understood. This narrative review summarizes the current evidence regarding the safety of melatonin in older adults (defined by age over 65 years). Melatonin appears to have a favorable safety profile in this population, however there is a dearth of evidence regarding the safety of prolonged use. There are several factors which increase the risk of adverse effects of melatonin in older adults, and these should be taken into consideration when prescribing to this population.

Keywords: adverse effect; elderly; insomnia; safety; sleep wake phase disorder.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349. doi:10.5664/jcsm.6470 - DOI - PMC - PubMed
    1. Li J, Somers VK, Xu H, Lopez-Jimenez F, Covassin N. Trends in use of melatonin supplements among US adults, 1999–2018. JAMA. 2022;327(5):483–485. doi:10.1001/jama.2021.23652 - DOI - PMC - PubMed
    1. Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175(16):3190–3199. doi:10.1111/bph.14116 - DOI - PMC - PubMed
    1. Kvetnoy I, Ivanov D, Mironova E, et al. Melatonin as the cornerstone of neuroimmunoendocrinology. Int J Mol Sci. 2022;23(3):1835. doi:10.3390/ijms23031835 - DOI - PMC - PubMed
    1. Peuhkuri K, Sihvola N, Korpela R. Dietary factors and fluctuating levels of melatonin. Food Nutr Res. 2012;56:17252. doi:10.3402/fnr.v56i0.17252 - DOI - PMC - PubMed

MeSH terms